Evidence map›Paper›PMID 25315265›Full record

ArticlePaediatric drugs2014

Optimized antimicrobial dosing strategies: a survey of pediatric hospitals.

Chad A Knoderer, Kristen R Nichols, Elaine G Cox

Abstract read
PubMed Publisher
In one paragraph

Article in Paediatric drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Aminoglycoside-induced nephrotoxicity in children.Pediatric nephrology (Berlin, Germany) · 2017
    Review
  3. Extended Infusion of Piperacillin/Tazobactam in Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
    Article
  4. Clinical Outcomes With Continuous Nafcillin Infusions in Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Chad A KnodererDepartment of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, 4600 Sunset Ave., Indianapolis, IN, 46208, USA, cknodere@butler.edu.
Kristen R Nichols
Elaine G Cox
Butler University · USIndiana University · USIndiana University School of Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtended-interval aminoglycoside (EIAG) and extended- and continuous-infusion β-lactam (EIBL and CIBL) dosing strategies are increasingly used in adults, but pediatric literature is limited.

objectiveThe objective of this study was to describe the use of EIAG, EIBL, and CIBL dosing in pediatric hospitals in the USA. STUDY DESIGN, SETTING, AND

participantsA national survey of children's hospitals was conducted. A single practitioner from each target hospital was identified through the Children's Hospital Association. Practice-based survey questions identified whether hospitals utilize EIAG, EIBL, and CIBL dosing.

main outcome measureThe main outcome measure was the percentage utilization of the dosing strategies, with secondary outcomes being the reasons for not using these dosing strategies.

resultsSeventy-seven of 215 identified practitioners (36 %) participated in the survey. EIAG, EIBL, and CIBL dosing were utilized in 63 %, 24 %, and 13 % of responding hospitals, respectively. The most common reasons for not using EIAG were concern regarding lack of efficacy data (56 %) and concern regarding the duration of the drug-free period (41 %). Respondents who did not utilize EIBL cited concern due to lack of pediatric EIBL efficacy data (54 %), the need for more intravenous access (54 %), intravenous medication compatibility issues (39 %), and the time during which the patient is attached to an intravenous infusion (31 %).

conclusionThis survey of children's hospitals indicates that EIAG is used in over 50 % of hospitals, but there is some lag in adoption of EIBL and CIBL dosing, both of which are used in fewer than 25 % of hospitals. Additional studies may provide much-needed evidence to increase the utilization of these strategies.

Indexed as

AminoglycosidesAnti-Bacterial AgentsAnti-Infective AgentsChildData CollectionHospitals, PediatricHumansInfusions, IntravenousOutcome Assessment, Health CareAminoglycosidesAnti-Bacterial AgentsAnti-Infective Agents

Identifiers

PMID25315265
OpenAlexW2074372101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.